Inotuzumab Biosimilar – Anti-CD22 mAb – Research Grade

Description of Inotuzumab Biosimilar - Anti-CD22 mAb - Research Grade

Introduction

Inotuzumab Biosimilar, also known as Anti-CD22 mAb, is a monoclonal antibody that has recently gained attention in the field of cancer research. This biosimilar is a highly specific and potent therapeutic agent that targets the CD22 antigen, which is overexpressed in various types of cancer cells. In this article, we will discuss the structure, activity, and potential applications of Inotuzumab Biosimilar as a research grade antibody.

Structure of Inotuzumab Biosimilar

Inotuzumab Biosimilar is a recombinant humanized monoclonal antibody that is composed of two heavy chains and two light chains. The antibody has a molecular weight of approximately 150 kDa and is produced through mammalian cell culture technology. The heavy and light chains are connected by disulfide bonds and form a Y-shaped structure. The variable regions of the antibody are responsible for binding to the CD22 antigen, while the constant regions determine the effector functions of the antibody.

Activity of Inotuzumab Biosimilar

Inotuzumab Biosimilar specifically targets the CD22 antigen, which is a transmembrane glycoprotein that is expressed on the surface of B-cells. This antigen plays a crucial role in B-cell development and function. In cancer cells, CD22 is overexpressed, making it an attractive therapeutic target for the treatment of B-cell malignancies. Inotuzumab Biosimilar binds to CD22 with high affinity and specificity, leading to the internalization and subsequent destruction of cancer cells through various mechanisms, such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

Additionally, Inotuzumab Biosimilar has been shown to have a dual mechanism of action by also targeting the CD22 antigen on regulatory T-cells (Tregs). Tregs play a role in suppressing the immune response and promoting tumor growth. By targeting and depleting Tregs, Inotuzumab Biosimilar can enhance the anti-tumor immune response and potentially improve the efficacy of other cancer therapies.

Applications of Inotuzumab Biosimilar

Inotuzumab Biosimilar has shown promising results in preclinical and clinical studies as a potential treatment for B-cell malignancies, such as B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin’s lymphoma (NHL). In a phase II clinical trial, Inotuzumab Biosimilar was shown to induce a complete response in 81% of patients with relapsed or refractory B-ALL. It has also shown efficacy as a single agent and in combination with other chemotherapeutic agents in patients with relapsed or refractory NHL.

Apart from its potential as a therapeutic agent, Inotuzumab Biosimilar also has applications in research. Its high specificity and affinity for the CD22 antigen make it a valuable tool for studying the role of CD22 in cancer development and progression. It can also be used to investigate the mechanisms of action of other CD22-targeting therapies and to develop new treatment strategies.

Conclusion

Inotuzumab Biosimilar, also known as Anti-CD22 mAb, is a highly specific and potent monoclonal antibody that targets the CD22 antigen, which is overexpressed in various types of cancer cells. Its unique structure and mechanism of action make it a promising therapeutic agent for the treatment of B-cell malignancies. In addition, its applications in research make it a valuable tool for studying the role of CD22 in cancer and developing new treatment strategies. Further research and clinical trials are needed to fully explore the potential of Inotuzumab Biosimilar as a therapeutic and research grade antibody.

SDS-PAGE for Inotuzumab Biosimilar - Anti-CD22 mAb

Inotuzumab Biosimilar - Anti-CD22 mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.